Search

Your search keyword '"Kudva, Anupa"' showing total 17 results
Start Over Author "Kudva, Anupa" Publication Type Academic Journals
17 results on '"Kudva, Anupa"'

1. Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE

Author

San-Miguel, Jesus, Avet-Loiseau, Hervé, Paiva, Bruno, Kumar, Shaji, Dimopoulos, Meletios A., Facon, Thierry, Mateos, María-Victoria, Touzeau, Cyrille, Jakubowiak, Andrzej, Usmani, Saad Z., Cook, Gordon, Cavo, Michele, Quach, Hang, Ukropec, Jon, Ramaswami, Priya, Pei, Huiling, Qi, Mia, Sun, Steven, Wang, Jianping, Krevvata, Maria, DeAngelis, Nikki, Heuck, Christoph, Van Rampelbergh, Rian, Kudva, Anupa, Kobos, Rachel, Qi, Ming, and Bahlis, Nizar J.

Published
2022
Full Text
View/download PDF

2. Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE

Author

Mateos, Maria-Victoria, Dimopoulos, Meletios A., Cavo, Michele, Suzuki, Kenshi, Knop, Stefan, Doyen, Chantal, Lucio, Paulo, Nagy, Zsolt, Pour, Ludek, Grosicki, Sebastian, Crepaldi, Andre, Liberati, Anna Marina, Campbell, Philip, Yoon, Sung-Soo, Iosava, Genadi, Fujisaki, Tomoaki, Garg, Mamta, Iida, Shinsuke, Bladé, Joan, Ukropec, Jon, Pei, Huiling, Van Rampelbergh, Rian, Kudva, Anupa, Qi, Ming, and San-Miguel, Jesus

Published
2021
Full Text
View/download PDF

3. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial

Author

Mateos, Maria-Victoria, Cavo, Michele, Blade, Joan, Dimopoulos, Meletios A, Suzuki, Kenshi, Jakubowiak, Andrzej, Knop, Stefan, Doyen, Chantal, Lucio, Paulo, Nagy, Zsolt, Pour, Ludek, Cook, Mark, Grosicki, Sebastian, Crepaldi, Andre, Liberati, Anna Marina, Campbell, Philip, Shelekhova, Tatiana, Yoon, Sung-Soo, Iosava, Genadi, Fujisaki, Tomoaki, Garg, Mamta, Krevvata, Maria, Chen, Ying, Wang, Jianping, Kudva, Anupa, Ukropec, Jon, Wroblewski, Susan, Qi, Ming, Kobos, Rachel, and San-Miguel, Jesus

Published
2020
Full Text
View/download PDF

4. Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial

Author

Knop, Stefan, Mateos, Maria-Victoria, Dimopoulos, Meletios A., Suzuki, Kenshi, Jakubowiak, Andrzej, Doyen, Chantal, Lucio, Paulo, Nagy, Zsolt, Usenko, Ganna, Pour, Ludek, Cook, Mark, Grosicki, Sebastian, Crepaldi, Andre, Liberati, Anna Marina, Campbell, Philip, Shelekhova, Tatiana, Yoon, Sung-Soo, Losava, Genadi, Fujisaki, Tomoaki, Garg, Mamta, Wang, Jianping, Wroblewski, Susan, Kudva, Anupa, Gries, Katharine S., Fastenau, John, San-Miguel, Jesus, and Cavo, Michele

Published
2021
Full Text
View/download PDF

6. Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma.

Author

Mateos, Maria-Victoria, Rigaudeau, Sophie, Basu, Supratik, Spicka, Ivan, Schots, Rik, Wrobel, Tomasz, Cook, Gordon, Beksac, Meral, Gries, Katharine S, Kudva, Anupa, Tromp, Brenda, Van Rampelbergh, Rian, Pei, Huiling, Wroblewski, Susan, Carson, Robin, Delioukina, Maria, and White, Darrell

Subjects
THERAPEUTIC use of monoclonal antibodies, GENERIC drug substitution, RANDOMIZED controlled trials, RESEARCH funding, DESCRIPTIVE statistics, MULTIPLE myeloma, STATISTICAL sampling, PATIENT safety
Abstract

Introduction: Two phase 3 studies demonstrated superior efficacy of intravenous daratumumab (DARA IV) plus bortezomib/melphalan/prednisone (ALCYONE) or lenalidomide/dexamethasone (Rd; MAIA) versus standard-of-care regimens for transplant-ineligible newly diagnosed multiple myeloma. In these studies, patients could switch from DARA IV to subcutaneous daratumumab (DARA SC) while receiving daratumumab monotherapy in ALCYONE (as of Cycle 11) or daratumumab plus Rd in MAIA. The phase 3 COLUMBA study demonstrated noninferiority of DARA SC to DARA IV. DARA SC reduced administration time, allowing patients to spend less time in healthcare settings, a relevant practical consideration for patient care in the COVID-19 pandemic/settings of limited healthcare resources. Methods: DARA SC 1800 mg was administered every 4 weeks, per approved dosing schedules. We evaluated safety and patient-reported experience (ALCYONE only) among patients who switched from DARA IV to DARA SC. Results: Fifty-seven patients in ALCYONE and 135 in MAIA switched to DARA SC. Three (2.2%; MAIA) patients reported injection-site reactions, all of which were mild. No infusion-related reactions occurred with DARA SC. In ALCYONE, >80% of patients preferred DARA SC over DARA IV. Grade 3/4 treatment-emergent adverse events (TEAEs) occurred in 5.3% of patients in ALCYONE and 25.9% in MAIA; one (0.7%; MAIA) patient experienced a TEAE with an outcome of death. Conclusion: For transplant-ineligible newly diagnosed multiple myeloma, DARA SC (monotherapy/with Rd) was safe and preferred over DARA IV. ClinicalTrials.gov, NCT02195479/NCT02252172. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

9. Sustained Minimal Residual Disease (MRD) Negativity and Clinical Efficacy in Transplant-Ineligible (TIE) Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Treated with Daratumumab-Based Regimens: Analysis of Maia and Alcyone

Author

San-Miguel, Jesus F., Avet-Loiseau, Herve, Paiva, Bruno, Kumar, Shaji K., Dimopoulos, Meletios A., Facon, Thierry, Mateos, Maria-Victoria, Touzeau, Cyrille, Jakubowiak, Andrzej, Usmani, Saad Z., Cook, Gordon, Cavo, Michele, Quach, Hang, Ukropec, Jon, Ramaswami, Priya, Pei, Huiling, Sun, Steven, Wang, Jianping, Krevvata, Maria, DeAngelis, Nikki, Heuck, Christoph, Van Rampelbergh, Rian, Kudva, Anupa, Kobos, Rachel, Qi, Ming, and Bahlis, Nizar J.

Published
2020
Full Text
View/download PDF

10. Long-Term Outcomes and Health-Related Quality of Life (HRQoL) By Response Status for Bortezomib, Melphalan, and Prednisone (VMP) ± Daratumumab (DARA) in Alcyone

Author

Rodriguez-Otero, Paula, Boccadoro, Mario, Hajek, Roman, Fujisaki, Tomoaki, Lee, Jae Hoon, Martinez-Lopez, Joaquin, Lucio, Paulo, Nagy, Zsolt, Usenko, Ganna, Liberati, Anna Marina, Lazaroiu, Mihaela, Woszczyk, Dariusz, Takamatsu, Hiroyuki, Romejko-Jarosinska, Joanna, Knop, Stefan Tobias, Pavlovsky, Astrid, Forsyth, Cecily, Ishikawa, Takayuki, Gries, Katharine S., Pei, Huiling, Kudva, Anupa, Ukropec, Jon, Wroblewski, Susan, Carson, Robin, and Dimopoulos, Meletios A

Published
2020
Full Text
View/download PDF

12. Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Overall Survival in Alcyone

Author

Mateos, Maria-Victoria, Cavo, Michele, Bladé, Joan, Dimopoulos, Meletios A., Suzuki, Kenshi, Jakubowiak, Andrzej, Knop, Stefan, Doyen, Chantal, Lucio, Paulo, Nagy, Zsolt, Pour, Ludek, Cook, Mark, Grosicki, Sebastian, Crepaldi, Andre H, Liberati, Anna Marina, Campbell, Philip, Shelekhova, Tatiana, Yoon, Sung-Soo, Iosava, Genadi, Fujisaki, Tomoaki, Garg, Mamta, Krevvata, Maria, Wang, Jianping, Kudva, Anupa, Ukropec, Jon, Wroblewski, Susan, Kobos, Rachel, and San-Miguel, Jesús

Published
2019
Full Text
View/download PDF

13. One-Year Update of a Phase 3 Randomized Study of Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) in Patients (Pts) with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM): Alcyone

Author

Dimopoulos, Meletios A, Mateos, Maria-Victoria, Cavo, Michele, Suzuki, Kenshi, Jakubowiak, Andrzej, Knop, Stefan, Doyen, Chantal, Lucio, Paulo, Nagy, Zsolt, Kaplan, Polina, Pour, Ludek, Cook, Mark, Grosicki, Sebastian, Crepaldi, Andre H, Liberati, Anna Marina, Campbell, Philip, Shelekhova, Tatiana, Yoon, Sung-Soo, Iosava, Genadi, Fujisaki, Tomoaki, Garg, Mamta, Chiu, Christopher, Wang, Jianping, Kudva, Anupa, Kobos, Rachel, Wroblewski, Susan, Qi, Ming, San-Miguel, Jesus F, and Bladé, Joan

Published
2018
Full Text
View/download PDF

15. Influenza A Inhibits Th17-Mediated Host Defense against Bacterial Pneumonia in Mice.

Author

Kudva, Anupa, Scheller, Erich V., Robinson, Keven M., Crowe, Chris R., Sun Mi Choi, Slight, Samantha R., Khader, Shabaana A., Dubin, Patricia J., Enelow, Richard I., Kolls, Jay K., and Alcorn, John F.

Subjects
*INFLUENZA A virus, *PNEUMONIA in animals, *LABORATORY mice, *STAPHYLOCOCCUS aureus, *DISEASE susceptibility
Abstract

Staphylococcus aureus is a significant cause of hospital and community acquired pneumonia and causes secondary infection after influenza A. Recently, patients with hyper-IgE syndrome, who often present with S. aureus infections of the lung and skin, were found to have mutations in STAT3, required for Th17 immunity, suggesting a potential critical role for Th17 cells in S. aureus pneumonia. Indeed, IL-17R-/- and IL-22-/- mice displayed impaired bacterial clearance of S. aureus compared with that of wild-type mice. Mice challenged with influenza A PR/8/34 H1N1 and subsequently with S. aureus had increased inflammation and decreased clearance of both virus and bacteria. Coinfection resulted in greater type I and II IFN production in the lung compared with that with virus infection alone. Importantly, influenza A coinfection resulted in substantially decreased IL-17, IL-22, and IL-23 production after S. aureus infection. The decrease in S. aureus-induced IL-17, IL-22, and IL-23 was independent of type II IFN but required type I IFN production in influenza A-infected mice. Furthermore, overexpression of IL-23 in influenza A, S. aureus-coinfected mice rescued the induction of IL-17 and IL-22 and markedly improved bacterial clearance. These data indicate a novel mechanism by which influenza A-induced type I IFNs inhibit Th17 immunity and increase susceptibility to secondary bacterial pneumonia. [ABSTRACT FROM AUTHOR]

Published
2011
Full Text
View/download PDF

17. Novel multiplex PCR-SSP method for centromeric KIR allele discrimination.

Author

Le Luduec, Jean-Benoît, Kudva, Anupa, Boudreau, Jeanette E., and Hsu, Katharine C.

Subjects
*LINKAGE disequilibrium, *INTERMEDIATES (Chemistry), *CELL transplantation, *PHYLOGENY, *CHROMOSOMES, *AMPLIFICATION reactions, *EUROPEAN Americans
Abstract

Allelic diversity of the KIR2DL receptors drive differential expression and ligand-binding affinities that impact natural killer cell function and patient outcomes for diverse cancers. We have developed a global intermediate resolution amplification-refractory mutation system (ARMS) PCR-SSP method for distinguishing functionally relevant subgroups of the KIR2DL receptors, as defined by phylogenetic study of the protein sequences. Use of the ARMS design makes the method reliable and usable as a kit, with all reactions utilizing the same conditions. Six reactions define six subgroups of KIR2DL1; four reactions define three subgroups of KIR2DL2; and five reactions define four subgroups of KIR2DL3. Using KIR allele data from a cohort of 426 European-Americans, we identified the most common KIR2DL subtypes and developed the high-throughput PCR-based methodology, which was validated on a separate cohort of 260 healthy donors. Linkage disequilibrium analysis between the different KIR2DL alleles revealed that seven allelic combinations represent more than 95% of the observed population genotypes for KIR2DL1/L2/L3. In summary, our findings enable rapid typing of the most common KIR2DL receptor subtypes, allowing more accurate prediction of co-inheritance and providing a useful tool for the discrimination of observed differences in surface expression and effector function among NK cells exhibiting disparate KIR2DL allotypes. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results